101 purchase as supplier for a total of 5.5 mil millones (5,459,442,792.844 ) between 2007 and 2018.
Overcost in MXN
5.7 millones pesos mexicanos (5,699,016.599 MXN)
Overcost in %
3.93 %
| Product | Purchases | Total amount | Overcost in MXN | Overcost in % | Period |
|---|---|---|---|---|---|
| VACUNA PENTAVALENTE CONTRA ROTAVIRUS | 12 | 859.2 millones MXN | 9.52 MXN | 0.00000103 % | 2012 - 2018 |
| VACUNA DOBLE VIRAL (SR) CONTRA SARAMPIÓN Y RUBÉOLA | 6 | 122.5 millones MXN | 1.9 millones MXN | 0.565 % | 2013 - 2016 |
| FABOTERÁPICO POLIVALENTE ANTIALACRÁN O FRAGMENTOS F(AB)2 DE INMUNOGLOBULINA POLIVALENTE ANTIALACRÁN | 6 | 89.9 millones MXN | 0.837 MXN | 0.000000929 % | 2014 - 2018 |
| SUSTANCIAS BIOLÓGICAS | 6 | 16.2 millones MXN | 2.2 millones MXN | 16 % | 2016 - 2018 |
| TOXOIDES TETÁNICO Y DIFTÉRICO(TD) | 5 | 11.9 millones MXN | 0 MXN | 0 % | 2015 - 2015 |
| TOXOIDES TETÁNICO Y DIFTÉRICO(TD) | 5 | 66.9 millones MXN | 0 MXN | 0 % | 2011 - 2013 |
| VACUNA TRIPLE VIRAL (SRP) CONTRA SARAMPIÓN RUBÉOLA Y PAROTIDITIS | 5 | 275.6 millones MXN | 645,917.6 MXN | 2.97 % | 2015 - 2018 |
| VACUNA PENTAVALENTE CONTRA ROTAVIRUS | 4 | 284 millones MXN | 4.14 MXN | 0.00000142 % | 2012 - 2012 |
| VACUNA RECOMBINANTE CONTRA LA HEPATITIS B | 4 | 71.4 millones MXN | 0 MXN | 0 % | 2015 - 2015 |
| VACUNA ANTIPOLIOMIELÍTICA BIVALENTE ORAL | 4 | 81.4 millones MXN | 0 MXN | 0 % | 2011 - 2012 |
Country
Entity type
profit
Identifiers
RFC: LBR990311Q29
Source(s)
Part of the project
Organization responsible for the import